Table of contents
Vulvar lichen planus
Guidelines
Key sources
The following summarized guidelines for the evaluation and management of vulvar lichen planus are prepared by our editorial team based on guidelines from the American College of Obstetricians and Gynecologists (ACOG 2020) and the European Academy of Dermatology and Venereology (EADV 2017).
1
2
Diagnostic investigations
Evaluation for oral involvement: as per ACOG 2020 guidelines, obtain evaluation of the oral cavity because oral involvement is common in patients with erosive lichen planus.
B
More topics in this section
Evaluation for comorbidities
Medical management
Corticosteroids, topical
As per EADV 2017 guidelines:
Offer ultrapotent topical corticosteroids such as clobetasol propionate in patients with VLP.
B
Insufficient evidence to recommend an optimal regimen for ultrapotent topical corticosteroids.
I
More topics in this section
Corticosteroids (vaginal)
Calcineurin inhibitors
Management of co-occurring infections
Therapeutic procedures
Follow-up and surveillance
Follow-up
As per EADV 2017 guidelines:
Obtain careful monitoring for all potentially toxic therapies (such as azathioprine, dapsone, griseofulvin, chloroquine, minocycline, cyclosporine, methotrexate, mycophenolate, retinoids, oral corticosteroids) preferably supervised by a dermatologist at a specialized clinic.
B
Assess active disease as clinically required. Ensure long-term specialized follow-up in patients with erosive VLP.
B